July 06, 2022
2 min watch
Save
VIDEO: Tyrvaya increases Schirmer’s score in patients with dry eye
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO – Tyrvaya nasal spray was shown to increase Schirmer’s scores in 4 weeks in the ONSET-1 and ONSET-2 clinical trials, Leslie O’Dell, OD, said at Optometry’s Meeting.
Patients using OC-01, or Tyrvaya (varenicline solution 0.03 mg, Oyster Point Pharma) increased by 5.5 mm, whether or not they started off with mild or severe dry eye, she said.
Published by:
Sources/Disclosures
Collapse
Source:
O’Dell L, et al. Effect of OC-01 (varenicline solution) nasal spray compared to vehicle control on dry eye disease sign outcomes by baseline subgroup characteristics.
Disclosures:
O’Dell reports being an advisory board member for Oyster Point Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.